Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
兩家頂級生物技術公司達成了用於臨床研究的****供應協議
Two separate deals hit the wires on Tuesday. One is PharmAla Biotech's (OTC:MDXXF) with Numinus Wellness (OTC:NUMIF) for a group therapy model with MDMA, the other is Optimi Health's (OTCQX:OPTHF) with Tel Aviv University for MDMA's potential effects on addiction treatment.
週二有兩筆單獨的交易即將到來。一個是PharMala Biotech（場外交易代碼：MDXXF）與Numinus Wellness（場外交易代碼：NUMIF）合作的使用****的團體治療模型，另一個是特拉維夫大學的Optimi Health（OTCQX: OPTHF），用於研究****對成癮治療的潛在影響。
PharmAla Signs Sale Agreement With Numinus
PharMala 與 Numinus 簽署銷售協議
PharmAla Biotech Holdings, a biotech company researching, developing and manufacturing proprietary MDMA "LaNeo" and new MDMA derivatives (aka MDXX-class molecules) entered into a binding sales agreement with Numinus Wellness to provide its GMP MDMA LaNeo for a prospective clinical trial, now holding for approval.
PharMala Biotech Holdings是一家研究、開發和製造專有的**** “LaneO” 和新的****衍生物（又名MDX級分子）的生物技術公司PharMala Biotech Holdings與Numinus Wellness簽訂了具有約束力的銷售協議，爲一項前瞻性的臨床試驗提供其GMP MDMA LaneO，該協議目前正在等待批准。
PharmAla's...
Ph...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。